Thank you for joining the weekly webinar! We are admitting audience members from the waiting room. **Please allow a few moments for the webinar to begin.**



HEALEY ALS Platform Trial

Weekly Q&A – May 16, 2024

Massachusetts General Hospital Founding Member, Mass General Brigham





Healey & AMG Center

Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital





















biohaven













🕷 TAMBOURINE

RUN2REVIVE MIND · BODY · POTENTIAL



Common protocol and shared infrastructure allow for operational and scientific efficiencies





Regimen G

Regimen F

Regimen E

Regimen D

Regimen C

Regimen B


Regimen A

1 Protocol (Phase 2/3) 1 single IRB Central Governance

7 Regimens 70+ Enrolling Sites ~1300 Participants

Regimen: Active Study Drug + Matching Placebo

The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug



Primary Endpoint (Placebo-Controlled Period)

Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival

Safety, Secondary, and Exploratory Endpoints

(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)

Enrollment Update: Regimen F and Regimen G

NEWS · 5 MINUTE READ · APR | 11 | 2024

The HEALEY ALS Platform Trial completes enrollment for testing investigational product ABBV-CLS-7262 from Calico Life Sciences

NEWS · 5 MINUTE READ · MAY | 1 | 2024

The HEALEY ALS Platform Trial completes enrollment for Regimen G evaluating investigational product DNL343 from Denali Therapeutics



https://bit.ly/3JChDCq


Shank You for your partnership in ALS research



https://bit.ly/3woUUGI

Navigating Clinical Trial Opportunities

ClinicalTrials.gov – <u>clinicaltrials.gov/</u>





- ALS TDI Trial Navigator <u>www.als.net/als-trial-navigator/</u>
- ALS Signal (I AM ALS) <u>www.iamals.org/get-help/als-signal-clinical-research-dashboard/</u>
- NEALS <u>neals.org/als-trials/neals-affiliated</u>
- MDA <u>www.mda.org/research/clinical-trials</u>
- ALSA <u>www.als.org/research/finding-als-research-opportunities</u>
- International Alliance of ALS/MND Associations <u>www.als-mnd.org/support-for-pals-</u> <u>cals/research/understanding-als-mnd-research/</u>



NEALS Educational Webinars

View Recording



https://bit.ly/3UIEUrt



An Overview of The ALS Better Care Act





ALS Better Care Act

 Establishes a single, flat \$800 payment per visit to providers caring for patients with ALS on Medicare beginning January 1, 2025.

Providing additional payment to ALS-related service providers will:

- Improve access to care for patients
- Extend survival
- Catalyze clinical research
- May offer financial savings due to improved outcomes (lower preventable costs)



The Act will give people living with ALS desperately needed access to multidisciplinary care and clinical trials. People with ALS who receive multidisciplinary care live longer and have a higher quality of life.

AMYOTROPHIC LATERAL SCLEROSIS

(ALS) (aka Lou Gehrig's disease) is a neurodegenerative condition affecting nerve cells that control voluntary muscular movement.

PEOPLE LIVING WITH ALS

(PLWALS) decline rapidly and require specialized care from multidisciplinary teams to address medical needs.

Medicare reimbursement does not adequately cover timely and effective care, hampering the ability of providers to research innovations to improve survival and quality of life, and reduce complications.

Adequately funded clinics could **lower preventable costs** and **long wait times**, extend survival, and simultaneously catalyze cutting-edge clinical research to accelerate the path to a cure.



NEALS Educational Webinars

Visit the NEALS website

to explore upcoming webinars or view previous recordings



https://bit.ly/3S4P0Sb



May 16, 2024 / 11:00 am-12:00 pm

Access for ALL in ALS (ALL ALS) Consortium

National Institutes of Health (NIH) funded "ALL ALS" consortium is a multiinstitutional effort that aims to organize the ALS clinical research landscape in the US. ALL ALS is operating in partnership with several stakeholders...

June 12, 2024 / 12:00 pm-1:00 pm

Promising Alternative and Off-Label Treatments for ALS

In this educational webinar, Dr. Richard Bedlack of ALSUntangled will review what he considers to be the most promising alternative and offlabel ALS treatments currently. These products, which include vitamins, supplements, and...

EAP Webpages and Resources

Link to EAP Website:



https://bit.ly/3uni3lc

About the Healey & AMG Center for Clinical Care & Research Platform Expanded ALS Trial Resources Opportunities Access Overview > Home - Neurology - ALS - Research F EAP Opportunities > X in For Patients > Expanding Access to . News & Webinars > Investigational Products EAP Opportunities > EAP News & Webinars > Information for Patients > EAP Opportunities Overview Current and upcoming expanded access protocols At the Sean M. Healey & AMG Center for ALS, we are dedicated to developing effective treatments for ALS and to providing people with ALS access to experimental therapies through Expanded Access Learn more >

Protocol (EAP) programs.

EAPs are a pathway for people with a life-threatening condition or serious disease to gain access to an investigational medical product when they are not eligible for a clinical trial. These investigational products - drugs, biologics, or medical devices - are currently being studied, but not yet approved by the US Food and Drug Administration (FDA). Alongside traditional data, EAPs can also provide data that may be useful in developing new therapies.

We have built a dedicated team at the Healey & AMG Center to rapidly implement EAPs for people with ALS at Mass General and are working with several other research centers across the US.

Supporting Expanded Access

Expanded Access Protocol programs at the Sean M. Healey and AMG Center for ALS are funded by multiple sources, including contributions from donors like you. Thank you for partnering with us in the quest to discover life-saving therapies for individuals affected by ALS.

EAP News & Webinars

Get the latest news and updates about expanded access protocols

News &

Events

Learn more >

Information for Patients

Common questions and helpful resources about expanded access

Learn more :

Give Now >

Community Support

First Participants Enrolled in the NIH-Funded Pridopidine and Rapa EAPs!



https://www.massgeneral.org/neurology/als/research/expanded-access-news Press Releases

- May 2024: The Sean M. Healey & AMG Center for ALS and Rapa Therapeutics announce first
 participant enrolled in Expanded Access to RAPA-501 Protocol (EAP)
- April 2024: <u>The Sean M. Healey & AMG Center for ALS and Prilenia Therapeutics Announce First</u> Participant Enrolled in NIH-Sponsored ACT for ALS Expanded Access Protocol for Pridopidine

NEWS · 5 MINUTE READ · MAY | 2 | 2024

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP

NEWS · 5 MINUTE READ · APR | 29 | 2024

The Sean M. Healey & AMG Center for ALS and Prilenia Therapeutics Announce First Participant Enrolled in NIH-Sponsored ACT for ALS Expanded Access Protocol for Pridopidine

Patient Navigation Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu




Catherine Small



registration:

Weekly webinar



May 23rd- Weekly Q&A webinar May 30th- Weekly Q&A webinar June 6th- Canceled

ALS Link sign-up:



https://bit.ly/3o2Ds3m

Allison Bulat